{"nctId":"NCT03782103","briefTitle":"In-vivo Efficacy of Patient Preoperative Prep, ZuraPrep (ZP)","startDateStruct":{"date":"2019-01-25","type":"ACTUAL"},"conditions":["Surgical Skin Preparation"],"count":156,"armGroups":[{"label":"ZuraPrep (70% IPA)","type":"EXPERIMENTAL","interventionNames":["Drug: ZuraPrep Clear Solution"]},{"label":"ChloraPrep","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ChloraPrep"]},{"label":"ZuraPrep Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: ZuraPrep Vehicle"]}],"interventions":[{"name":"ZuraPrep Clear Solution","otherNames":["Isopropyl alcohol 70%","ZP"]},{"name":"ChloraPrep","otherNames":["CHG 2%/IPA 70%","Chlorhexidine gluconate 2% / Isopropyl alcohol 70%"]},{"name":"ZuraPrep Vehicle","otherNames":["Vehicle"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects of any race\n* Subjects in good general health\n* Minimum bacterial baseline requirements on abdomen and groin\n* Skin free of tattoos, dermatoses, abrasions, cuts, lesions, or other skin disorder near or on the applicable test area.\n\nExclusion Criteria:\n\n* Topical or systemic antimicrobial exposure within 14 days prior to screening and treatment days, including antibiotics.\n* Taking antihistamines, immunosuppressants, or oral steroids within 14 days prior to screening and treatment days, excluding contraception or post-menopausal treatment.\n* Subjects with allergies to study materials including isopropyl alcohol or chlorhexidine gluconate.\n* Subjects with a history of skin sensitivity, skin allergies, or skin cancer.\n* Subjects who are pregnant, attempting pregnancy or nursing.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Bacterial Reduction - Groin","description":"A 3-log10 CFU/cm\\^2 bacterial reduction on the inguinal region is considered a success.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.133","spread":"0.4"},{"groupId":"OG001","value":"3.642","spread":"0.5"},{"groupId":"OG002","value":"1.277","spread":"0.6"}]}]}]},{"type":"PRIMARY","title":"Bacterial Reduction - Abdomen","description":"A 2-log10 CFU/cm\\^2 bacterial reduction on the abdomen region is considered a success.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.036","spread":"0.4"},{"groupId":"OG001","value":"3.087","spread":"0.4"},{"groupId":"OG002","value":"1.234","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Bacterial Counts Not Exceeding Baseline in the Abdomen and Groin Region","description":"Bacterial counts should not exceed baseline on the abdomen or groin region","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":156},"commonTop":[]}}}